Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy

Research output: Contribution to journalReviewpeer-review

  1. The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting

    Research output: Contribution to journalReviewpeer-review

  1. Loss of Ambra1 promotes melanoma growth and invasion

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Midkine-A potential therapeutic target in melanoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFβ-expressing cancer cells in a TGFβ-dependent manner

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Michael Friedrich
  • Simon Jasinski-Bergner
  • Maria-Filothei Lazaridou
  • Karthikeyan Subbarayan
  • Chiara Massa
  • Sandy Tretbar
  • Anja Mueller
  • Diana Handke
  • Katharina Biehl
  • Jürgen Bukur
  • Marco Donia
  • Ofer Mandelboim
  • Barbara Seliger
View graph of relations

Immunotherapy aims to activate the immune system to fight cancer in a very specific and targeted manner. Despite the success of different immunotherapeutic strategies, in particular antibodies directed against checkpoints as well as adoptive T-cell therapy, the response of patients is limited in different types of cancers. This attributes to escape of the tumor from immune surveillance and development of acquired resistances during therapy. In this review, the different evasion and resistance mechanisms that limit the efficacy of immunotherapies targeting tumor-associated antigens presented by major histocompatibility complex molecules on the surface of the malignant cells are summarized. Overcoming these escape mechanisms is a great challenge, but might lead to a better clinical outcome of patients and is therefore currently a major focus of research.

Original languageEnglish
JournalCancer immunology, immunotherapy
Volume68
Issue number10
Pages (from-to)1689-1700
Number of pages12
ISSN0340-7004
DOIs
Publication statusPublished - Oct 2019

    Research areas

  • Immune escape, Immunotherapy, MHC, Resistance, TIMO XIV, Tumor, HLA-G Antigens/physiology, Tumor Escape, Immunotherapy/methods, Humans, Histocompatibility Antigens Class I/immunology, Neoplasms/therapy, Antigen Presentation, Programmed Cell Death 1 Receptor/antagonists & inhibitors

ID: 57730672